Opinion Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan’s 2019 Health Care Investor Conference, one of the biggest events in the life sciences calendar and a fantastic indicator of what is to come in healthcare for the year ahead. Here, Crean gives us the inside scoop. …

Opinion Carla Smith is a healthcare thought leader with nearly 30 years’ experience. She champions transformational strategy, governance, and policy in the health sector, particularly in the areas of digital health and health IT. In this article, Ms Smith discusses the massive potential of digital therapeutics in helping patients manage their…

Opinion After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here Monica discusses the incredibly low rate of treatment options for…

Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…

USA Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) weighs in on the issue of drug shortages in America.    An uncertain environment for generic manufacturers imperils the sustainability of patient access to low-cost generic medicines.   The unavailability of prescription medicines can cause physical suffering,…

Mexico David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies.   In Mexico, approximately 15 percent of patients treated with therapies for rare diseases, dismiss the concept of adherence to treatments. In Latin American Countries such as Mexico, keeping…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here Thompson discusses the need for stronger public-private sector alliances in the push towards universal…

Canada Jan Hux is the President and CEO of Diabetes Canada. Canadians have been at the forefront of tackling diabetes since the discovery of insulin. Now that the disease has become an epidemic, measures must be put in place to tackle it at a population level.   If diabetes prevalence were…

USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the venture investment activity in life sciences for the past year.    In order to have a successful life sciences R&D program, biotech and pharma companies must develop game-changing therapeutics, companion diagnostics and personalized…

Genomics Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis and Kevin Allison is the director of geo-technology. Together they look at last week’s shock revelation of two CRISPR* babies who were born in China and the added tensions this might cause with the USA.    Aside from the immediate implications for US-China strategic competition, the…

USA With an increasing number of NFL players relying on potentially dangerous prescription painkillers, does the league need to relax its attitude to medical cannabis?   The US National Football League (NFL) is a juggernaut. Even with decreased television ratings in 2017, the league’s revenue was up. Each of the NFL’s…

USA Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) discusses the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES) and how it will improve access to medicines and restore healthy competition to the market.    American taxpayers, along with millions of patients, will benefit…